SAN DIEGO, Sept. 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc.
(Nasdaq: ANDS) announced today that it will present at the JMP Securities 3rd
Annual Healthcare Focus Conference on Tuesday, October 7, 2008 at 3:00 p.m.
EDT (12:00 p.m. PDT). The conference is being held at Le Parker Meridien in
New York City.
Steve Worland, Ph.D., President and Chief Executive Officer of Anadys,
will present an overview of Anadys and its three clinical programs: ANA598 and
ANA773 in hepatitis C and ANA773 in cancer.
The presentation will be simultaneously webcast and can be accessed on the
Investor Relations page of the Company's website at
http://www.anadyspharma.com. Listeners are encouraged to visit the website
approximately five minutes prior to the corporate presentation to download or
install any necessary software. A replay of the presentation will be
available approximately one hour after the live webcast concludes and will be
available through October 21, 2008.
About Anadys
Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
dedicated to improving patient care by developing novel medicines in the areas
of hepatitis C and oncology. For the treatment of chronic hepatitis C, the
Company is developing two potentially complementary agents, ANA598, a
non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug.
The Company is also developing ANA773 for the treatment of cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical in
nature constitute 'forward-looking statements.' Such statements include, but
are not limited to, references to Anadys' strategy, development programs, and
ability to develop novel medicines in the areas of hepatitis C and oncology.
Such forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause Anadys' actual results to be materially
different from historical results or from any results expressed or implied by
such forward-looking statements. For example, the results of preclinical
studies may not be predictive of future results, and Anadys cannot provide any
assurances that ANA598 and ANA773 will not have unforeseen safety issues, will
have favorable results in future clinical trials or will receive regulatory
approval. Risk factors that may cause actual results to differ are discussed
in Anadys' SEC filings, including Anadys' Form 10-K for the year ended
December 31, 2007 and Anadys' Form 10-Q for the quarter ended June 30, 2008.
All forward-looking statements are qualified in their entirety by this
cautionary statement. Anadys is providing this information as of this date
and does not undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future events or
otherwise.
SOURCE Anadys Pharmaceuticals, Inc.
